Efficacy and safety of vilazodone 20 mg and 40 mg in major depressive disorder: A randomized, double-blind, placebo- and active-controlled trial

被引：0
|
作者：
Gommoll, C. [1 ]
Mathews, M. [1 ]
Chen, D. [1 ]
Nunez, R. [1 ]
Khan, A. [1 ]
机构：
[1] Forest Res Inst, Jersey City, NJ USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2014年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-23-011
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [31] Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
    Bakish, David
    Bose, Anjana
    Gommoll, Carl
    Chen, Changzheng
    Nunez, Rene
    Greenberg, William M.
    Liebowitz, Michael
    Khan, Arif
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2014, 39 (01): : 40 - 49
  • [32] Efficacy and Safety of Vortioxetine (5, 10, and 20 mg) in Relapse Prevention: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study in Adults With Major Depressive Disorder (MDD)
    Thase, Michael
    Hanson, Elizabeth
    Jacobsen, Paula
    Xu, Rengyi
    Murthy, Naga Venkatesha
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 132 - 132
  • [33] Efficacy and safety of agomelatine (25 mg/50 mg), a melatonergic and specific serotonergic antidepressant, in the treatment of major depressive disorder: A randomised, double-blind placebo-controlled study
    Emsley, R
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S350 - S351
  • [34] Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial
    Kato, Masaki
    Nakagome, Kazuyuki
    Baba, Takamichi
    Sonoyama, Takuhiro
    Okutsu, Daiki
    Yamanaka, Hideki
    Shimizu, Ryosuke
    Motomiya, Tomoko
    Inoue, Takeshi
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2023, 77 (09) : 497 - 509
  • [35] RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL OF TAPENTADOL EXTENDED RELEASE FOR CHRONIC LOW BACK PAIN
    Shapiro, Douglas
    Buynak, Robert
    Okamoto, Akiko
    Van Hove, Ilse
    Steup, Achim
    Lange, Bernd
    Haufel, Thomas
    Etropolski, Mila
    RHEUMATOLOGY, 2010, 49 : I78 - I79
  • [36] Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial
    Berger, William E.
    Milgrom, Henry
    Skoner, David P.
    Tripp, Kenneth
    Parsey, Merdad V.
    Baumgartner, Rudolf A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (06) : 1217 - 1226
  • [37] The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study
    Wang, Xiaoliang
    Fan, Yimin
    Li, Guanjun
    Li, Huafang
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (03) : 133 - 139
  • [38] A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
    Garakani, Amir
    Martinez, Jose M.
    Marcus, Sue
    Weaver, James
    Rickels, Karl
    Fava, Maurizio
    Hirschowitz, Jack
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (05) : 269 - 275
  • [39] A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder
    Septien-Velez, Lucia
    Pitrosky, Bruno
    Padmanabhan, Sudharshan Krishna
    Germain, Jean-Michel
    Tourian, Karen A.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (06) : 338 - 347
  • [40] Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
    Kornstein, Susan
    Chang, Cheng-Tao
    Gommoll, Carl P.
    Edwards, John
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (04) : 217 - 223
12345